[SCHEDULE 13G] Southwest Gas Holdings, Inc. SEC Filing
Amendment No. 4 to Schedule 13G discloses that FMR LLC, a Delaware parent holding company, and its controlling person Abigail P. Johnson beneficially own 19,946,433 shares of Structure Therapeutics Inc. (CUSIP 86366E106), representing 11.6 % of the company鈥檚 outstanding common stock as of 30 June 2025.
- Sole voting power: 19,946,433 shares
- Sole dispositive power: 19,946,433 shares
- Shared voting/dispositive power: 0
The filing, submitted under Rule 13d-1(b), classifies FMR as a 鈥減arent holding company / control person.鈥� The certification states the position is not intended to influence control of the issuer. Exhibit 99 lists the relevant subsidiaries.
Crossing the 10 % threshold makes FMR a significant institutional shareholder; future changes in its position could meaningfully affect GPCR鈥檚 float, liquidity and perception among investors.
L'Emendamento n. 4 al Modulo 13G rivela che FMR LLC, una societ脿 madre del Delaware, e la sua persona di controllo Abigail P. Johnson possiedono beneficiariamente 19.946.433 azioni di Structure Therapeutics Inc. (CUSIP 86366E106), rappresentando il 11,6% del capitale sociale ordinario in circolazione al 30 giugno 2025.
- Potere di voto esclusivo: 19.946.433 azioni
- Potere dispositive esclusivo: 19.946.433 azioni
- Potere di voto/dispositivo condiviso: 0
La dichiarazione, presentata ai sensi della Regola 13d-1(b), classifica FMR come 鈥渟ociet脿 madre / persona di controllo.鈥� La certificazione afferma che la posizione non 猫 intesa a influenzare il controllo dell鈥檈mittente. L鈥橢xhibit 99 elenca le controllate rilevanti.
Il superamento della soglia del 10% rende FMR un azionista istituzionale significativo; eventuali modifiche future nella sua posizione potrebbero influenzare in modo rilevante il flottante, la liquidit脿 e la percezione di GPCR tra gli investitori.
La Enmienda N潞 4 al Anexo 13G revela que FMR LLC, una empresa matriz de Delaware, y su persona de control Abigail P. Johnson poseen beneficiosamente 19.946.433 acciones de Structure Therapeutics Inc. (CUSIP 86366E106), representando el 11,6% de las acciones ordinarias en circulaci贸n a 30 de junio de 2025.
- Poder de voto exclusivo: 19.946.433 acciones
- Poder dispositive exclusivo: 19.946.433 acciones
- Poder de voto/dispositivo compartido: 0
La presentaci贸n, realizada bajo la Regla 13d-1(b), clasifica a FMR como una 鈥渆mpresa matriz / persona de control.鈥� La certificaci贸n indica que la posici贸n no pretende influir en el control del emisor. El Anexo 99 enumera las subsidiarias relevantes.
Al superar el umbral del 10%, FMR se convierte en un accionista institucional significativo; futuros cambios en su posici贸n podr铆an afectar significativamente el flotante, la liquidez y la percepci贸n de GPCR entre los inversores.
靾橃爼鞎� 4順� Schedule 13G鞐� 霐半ゴ氅�, FMR LLC霛茧姅 雿鸽澕鞗柎 靻岇灛 氇殞靷檧 攴� 歆�氚办澑 Abigail P. Johnson鞚� Structure Therapeutics Inc. (CUSIP 86366E106)鞚� 19,946,433欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 2025雲� 6鞗� 30鞚� 旮办鞙茧 須岇偓鞚� 氤错喌欤� 氚滍枆欤检嫕 齑濎垬鞚� 11.6%鞐� 頃措嫻頃╇媹雼�.
- 雼弲 鞚橁舶甓�: 19,946,433欤�
- 雼弲 觳橂秳甓�: 19,946,433欤�
- 瓿惦彊 鞚橁舶甓�/觳橂秳甓�: 0欤�
頃措嫻 鞝滌稖靹滊姅 Rule 13d-1(b)鞐� 霐半澕 FMR鞚� 鈥橂须岇偓/歆赌氚办澑鈥�鞙茧 攵勲頃╇媹雼�. 鞚胳靹滌棎電� 鞚� 歆�攵� 氤挫湢臧� 氚滍枆鞚胳潣 歆�氚瓣秾 頄夓偓 鞚橂弰臧� 鞎勲嫎鞚� 氇呾嫓頃橁碃 鞛堨姷雼堧嫟. 攵�靻嶌劀 99鞐愲姅 甏�霠� 鞛愴殞靷皜 雮橃棿霅橃柎 鞛堨姷雼堧嫟.
10% 旮办靹犾潉 雱橃潓鞙茧鞃� FMR鞚� 欷戩殧頃� 旮瓣磤 韴瀽鞛�臧� 霅橃棃鞙茧┌, 頄ロ泟 歆�攵� 氤�頇旊姅 GPCR鞚� 鞙犿喌 欤检嫕 靾�, 鞙犽彊靹� 氚� 韴瀽鞛� 鞚胳嫕鞐� 韥� 鞓來枼鞚� 氙胳範 靾� 鞛堨姷雼堧嫟.
L'amendement n掳 4 au Schedule 13G r茅v猫le que FMR LLC, une soci茅t茅 m猫re du Delaware, et sa personne contr么lante Abigail P. Johnson d茅tiennent effectivement 19 946 433 actions de Structure Therapeutics Inc. (CUSIP 86366E106), repr茅sentant 11,6 % des actions ordinaires en circulation au 30 juin 2025.
- Pouvoir de vote exclusif : 19 946 433 actions
- Pouvoir de disposition exclusif : 19 946 433 actions
- Pouvoir de vote/disposition partag茅 : 0
Le d茅p么t, soumis en vertu de la r猫gle 13d-1(b), classe FMR comme une 芦 soci茅t茅 m猫re / personne de contr么le 禄. La certification indique que la position n'a pas pour but d'influencer le contr么le de l'茅metteur. L'exhibit 99 r茅pertorie les filiales concern茅es.
Le d茅passement du seuil de 10 % fait de FMR un actionnaire institutionnel significatif ; les changements futurs de sa position pourraient affecter de mani猫re significative le flottant, la liquidit茅 et la perception de GPCR parmi les investisseurs.
Nachtrag Nr. 4 zum Schedule 13G offenbart, dass FMR LLC, eine Muttergesellschaft aus Delaware, und ihre kontrollierende Person Abigail P. Johnson wirtschaftlich 19.946.433 Aktien von Structure Therapeutics Inc. (CUSIP 86366E106) besitzen, was zum 30. Juni 2025 11,6 % der ausstehenden Stammaktien des Unternehmens entspricht.
- Alleiniges Stimmrecht: 19.946.433 Aktien
- Alleiniges Verf眉gungsrecht: 19.946.433 Aktien
- Geteiltes Stimm-/Verf眉gungsrecht: 0
Die Einreichung, eingereicht gem盲脽 Regel 13d-1(b), klassifiziert FMR als 鈥濵uttergesellschaft / Kontrollperson鈥�. Die Zertifizierung besagt, dass die Position nicht darauf abzielt, die Kontrolle 眉ber den Emittenten zu beeinflussen. Anhang 99 listet die relevanten Tochtergesellschaften auf.
Das 脺berschreiten der 10-%-Schwelle macht FMR zu einem bedeutenden institutionellen Aktion盲r; zuk眉nftige 脛nderungen der Beteiligung k枚nnten den Streubesitz, die Liquidit盲t und die Wahrnehmung von GPCR bei Investoren erheblich beeinflussen.
- Strong institutional backing: FMR LLC鈥檚 11.6 % stake indicates sizeable confidence from a leading asset manager.
- Enhanced liquidity: Large passive ownership can support daily trading volumes and price stability.
- Ownership concentration: One holder controls over 10 % of shares, posing potential influence risk if intent changes.
Insights
TL;DR: Fidelity鈥檚 FMR reports 11.6 % GPCR stake鈥攊nformative but not immediately valuation-moving.
FMR鈥檚 19.9 M-share holding confirms robust institutional interest in Structure Therapeutics. While no purchase or sale details are provided, disclosure above 10 % signals monitoring visibility; any subsequent changes must be reported promptly, offering investors a window into Fidelity鈥檚 conviction. The filing alone does not alter fundamentals, but reinforces liquidity support and potential passive voting influence.
TL;DR: New 13G/A flags concentrated ownership; governance impact limited for now.
Because the position is reported on Schedule 13G鈥攏ot 13D鈥擣MR certifies a passive intent, implying no immediate push for board or control changes. Abigail P. Johnson鈥檚 dispositive but non-voting stance aligns with Fidelity鈥檚 customary structure. Still, a single holder controlling >10 % can sway shareholder votes if stance shifts. Investors should track any conversion to 13D, which would indicate activist intent.
L'Emendamento n. 4 al Modulo 13G rivela che FMR LLC, una societ脿 madre del Delaware, e la sua persona di controllo Abigail P. Johnson possiedono beneficiariamente 19.946.433 azioni di Structure Therapeutics Inc. (CUSIP 86366E106), rappresentando il 11,6% del capitale sociale ordinario in circolazione al 30 giugno 2025.
- Potere di voto esclusivo: 19.946.433 azioni
- Potere dispositive esclusivo: 19.946.433 azioni
- Potere di voto/dispositivo condiviso: 0
La dichiarazione, presentata ai sensi della Regola 13d-1(b), classifica FMR come 鈥渟ociet脿 madre / persona di controllo.鈥� La certificazione afferma che la posizione non 猫 intesa a influenzare il controllo dell鈥檈mittente. L鈥橢xhibit 99 elenca le controllate rilevanti.
Il superamento della soglia del 10% rende FMR un azionista istituzionale significativo; eventuali modifiche future nella sua posizione potrebbero influenzare in modo rilevante il flottante, la liquidit脿 e la percezione di GPCR tra gli investitori.
La Enmienda N潞 4 al Anexo 13G revela que FMR LLC, una empresa matriz de Delaware, y su persona de control Abigail P. Johnson poseen beneficiosamente 19.946.433 acciones de Structure Therapeutics Inc. (CUSIP 86366E106), representando el 11,6% de las acciones ordinarias en circulaci贸n a 30 de junio de 2025.
- Poder de voto exclusivo: 19.946.433 acciones
- Poder dispositive exclusivo: 19.946.433 acciones
- Poder de voto/dispositivo compartido: 0
La presentaci贸n, realizada bajo la Regla 13d-1(b), clasifica a FMR como una 鈥渆mpresa matriz / persona de control.鈥� La certificaci贸n indica que la posici贸n no pretende influir en el control del emisor. El Anexo 99 enumera las subsidiarias relevantes.
Al superar el umbral del 10%, FMR se convierte en un accionista institucional significativo; futuros cambios en su posici贸n podr铆an afectar significativamente el flotante, la liquidez y la percepci贸n de GPCR entre los inversores.
靾橃爼鞎� 4順� Schedule 13G鞐� 霐半ゴ氅�, FMR LLC霛茧姅 雿鸽澕鞗柎 靻岇灛 氇殞靷檧 攴� 歆�氚办澑 Abigail P. Johnson鞚� Structure Therapeutics Inc. (CUSIP 86366E106)鞚� 19,946,433欤茧ゼ 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅�, 鞚措姅 2025雲� 6鞗� 30鞚� 旮办鞙茧 須岇偓鞚� 氤错喌欤� 氚滍枆欤检嫕 齑濎垬鞚� 11.6%鞐� 頃措嫻頃╇媹雼�.
- 雼弲 鞚橁舶甓�: 19,946,433欤�
- 雼弲 觳橂秳甓�: 19,946,433欤�
- 瓿惦彊 鞚橁舶甓�/觳橂秳甓�: 0欤�
頃措嫻 鞝滌稖靹滊姅 Rule 13d-1(b)鞐� 霐半澕 FMR鞚� 鈥橂须岇偓/歆赌氚办澑鈥�鞙茧 攵勲頃╇媹雼�. 鞚胳靹滌棎電� 鞚� 歆�攵� 氤挫湢臧� 氚滍枆鞚胳潣 歆�氚瓣秾 頄夓偓 鞚橂弰臧� 鞎勲嫎鞚� 氇呾嫓頃橁碃 鞛堨姷雼堧嫟. 攵�靻嶌劀 99鞐愲姅 甏�霠� 鞛愴殞靷皜 雮橃棿霅橃柎 鞛堨姷雼堧嫟.
10% 旮办靹犾潉 雱橃潓鞙茧鞃� FMR鞚� 欷戩殧頃� 旮瓣磤 韴瀽鞛�臧� 霅橃棃鞙茧┌, 頄ロ泟 歆�攵� 氤�頇旊姅 GPCR鞚� 鞙犿喌 欤检嫕 靾�, 鞙犽彊靹� 氚� 韴瀽鞛� 鞚胳嫕鞐� 韥� 鞓來枼鞚� 氙胳範 靾� 鞛堨姷雼堧嫟.
L'amendement n掳 4 au Schedule 13G r茅v猫le que FMR LLC, une soci茅t茅 m猫re du Delaware, et sa personne contr么lante Abigail P. Johnson d茅tiennent effectivement 19 946 433 actions de Structure Therapeutics Inc. (CUSIP 86366E106), repr茅sentant 11,6 % des actions ordinaires en circulation au 30 juin 2025.
- Pouvoir de vote exclusif : 19 946 433 actions
- Pouvoir de disposition exclusif : 19 946 433 actions
- Pouvoir de vote/disposition partag茅 : 0
Le d茅p么t, soumis en vertu de la r猫gle 13d-1(b), classe FMR comme une 芦 soci茅t茅 m猫re / personne de contr么le 禄. La certification indique que la position n'a pas pour but d'influencer le contr么le de l'茅metteur. L'exhibit 99 r茅pertorie les filiales concern茅es.
Le d茅passement du seuil de 10 % fait de FMR un actionnaire institutionnel significatif ; les changements futurs de sa position pourraient affecter de mani猫re significative le flottant, la liquidit茅 et la perception de GPCR parmi les investisseurs.
Nachtrag Nr. 4 zum Schedule 13G offenbart, dass FMR LLC, eine Muttergesellschaft aus Delaware, und ihre kontrollierende Person Abigail P. Johnson wirtschaftlich 19.946.433 Aktien von Structure Therapeutics Inc. (CUSIP 86366E106) besitzen, was zum 30. Juni 2025 11,6 % der ausstehenden Stammaktien des Unternehmens entspricht.
- Alleiniges Stimmrecht: 19.946.433 Aktien
- Alleiniges Verf眉gungsrecht: 19.946.433 Aktien
- Geteiltes Stimm-/Verf眉gungsrecht: 0
Die Einreichung, eingereicht gem盲脽 Regel 13d-1(b), klassifiziert FMR als 鈥濵uttergesellschaft / Kontrollperson鈥�. Die Zertifizierung besagt, dass die Position nicht darauf abzielt, die Kontrolle 眉ber den Emittenten zu beeinflussen. Anhang 99 listet die relevanten Tochtergesellschaften auf.
Das 脺berschreiten der 10-%-Schwelle macht FMR zu einem bedeutenden institutionellen Aktion盲r; zuk眉nftige 脛nderungen der Beteiligung k枚nnten den Streubesitz, die Liquidit盲t und die Wahrnehmung von GPCR bei Investoren erheblich beeinflussen.
FAQ
How many Structure Therapeutics (GPCR) shares does FMR LLC own?
What percentage of GPCR鈥檚 outstanding stock does this represent?
Does FMR LLC have voting power over these shares?
Is FMR seeking control of Structure Therapeutics?
Who signed the filing on behalf of FMR and Abigail P. Johnson?
